BRIEF: Xuanzhu Biopharma launches IPO to raise $100 million
Xuanzhu Biopharmaceutical Co., Ltd. (2575.HK), spun off from Sihuan Pharma (0460.HK), launched its IPO on Monday, aiming to sell 67.3 million shares for HK$11.60 each to raise HK$780 million ($100 million). Subscriptions close on Oct. 10, with a trading debut set for Oct. 15 in Hong Kong.
The company has more than 10 drugs under development covering digestive diseases, oncology and non-alcoholic steatohepatitis (NASH).
Xuanzhu remains unprofitable, reporting its net loss widened last year to 556 million yuan from a net loss of 300 million yuan in 2023. It attributed the growing losses to sharp increases in administrative spending, including costs related to last year’s IPO application. The company reported a net loss of 111 million yuan in the first half of this year, similar to what it reported in the year-ago period.
By Lau Chi Hang
To subscribe to Bamboo Works weekly free newsletter, click here
Related Articles
BRIEF: China Resources to re-domicile two Hong Kong-listed units
BRIEF: Baiyunshan invests $105 million for 11% of NanJing Pharma
RELATED ARTICLES
-
BRIEF: Shuangdeng launches Hong Kong IPO to raise $118 million
6960.HK - BRIEF: Newtrend launches Hong Kong IPO to raise up to $31 million
-
BRIEF: Hipine launches Hong Kong IPO to raise up to $44 million
2583.HK
-
BRIEF: CF PharmTech to raise $77 million in Hong Kong IPO
2652.HK
- Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
- BRIEF: Innogen launches $87 million Hong Kong IPO
-
BRIEF: Cloudbreak launches $78 million Hong Kong IPO
2592.HK
